Ken Griffin Tenaya Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 74,300 shares of TNYA stock, worth $89,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,300

Previous 900 8155.56%

Holding current value

$89,160

Previous $1,000 10500.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$1.23 - $3.78 $2.33 Million - $7.17 Million	-1,896,265 Reduced 81.21%	438,886 $627,000
Q3 2024 Nov 14, 2024	BUY	$1.93 - $3.99 $370,710 - $766,391	192,078 Added 8.96%	2,335,151 $4.51 Million
Q2 2024 Aug 14, 2024	SELL	$2.72 - $4.99 $284,084 - $521,170	-104,443 Reduced 4.65%	2,143,073 $6.64 Million
Q1 2024 May 15, 2024	BUY	$2.88 - $6.8 $709,375 - $1.67 Million	246,311 Added 12.31%	2,247,516 $11.8 Million
Q4 2023 Feb 14, 2024	SELL	$1.73 - $3.39 $181,082 - $354,838	-104,672 Reduced 4.97%	2,001,205 $6.48 Million
Q3 2023 Nov 14, 2023	BUY	$2.55 - $5.65 $2.78 Million - $6.16 Million	1,090,819 Added 107.46%	2,105,877 $5.37 Million
Q2 2023 Aug 14, 2023	SELL	$2.64 - $7.64 $221,818 - $641,928	-84,022 Reduced 7.64%	1,015,058 $5.96 Million
Q1 2023 May 15, 2023	SELL	$1.92 - $3.59 $63,342 - $118,437	-32,991 Reduced 2.91%	1,099,080 $3.13 Million
Q4 2022 Feb 14, 2023	BUY	$1.68 - $3.19 $1.54 Million - $2.92 Million	914,733 Added 420.88%	1,132,071 $2.28 Million
Q3 2022 Nov 14, 2022	BUY	$2.9 - $5.88 $488,296 - $990,062	168,378 Added 343.91%	217,338 $631,000

Others Institutions Holding TNYA

# of Institutions

Shares Held

43.7M

Call Options Held

74.3K

Put Options Held

192K

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $49.6M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account